Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as a nominated preclinical candidate following AI‑driven design and preclinical validation. The company emphasized the molecule’s peripheral restriction to limit CNS exposure and its optimized anti‑inflammatory profile. Insilico also highlighted its participation at WHX 2026 to showcase translational partnerships and AI pipelines. These moves underline continued industry adoption of generative AI to accelerate candidate nomination. For pharma partners, Insilico’s approach illustrates how computational design can move molecules from concept to preclinical nomination faster, while raising questions around model interpretability, validation and downstream CMC and safety development.